IDH1 inhibitors show strong efficacy and tolerability in IDH1-mutated AML and MDS, with some patients achieving long-term ...
Clinical Trials Arena on MSN
Inhibrx Biosciences’ stock soars on chondrosarcoma Phase II victory
Inhibrx Biosciences is vying for approval of its targeted therapy, ozekibart, in chondrosarcoma. This follows the positive ...
Servier looks like it could bring a second IDH inhibitor from its 2021 takeover of Agios’ oncology business to market, after reporting positive results in a phase 3 brain cancer trial. The drug ...
Copyright: © 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
Contributed by Tak W. Mak; received May 24, 2022; accepted December 12, 2022; reviewed by Timothy J. Ley and Ravindra Majeti ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback